Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants

Ohlsson, Arne; Walia, Rajneesh; Shah, Sachin S

doi:10.1002/14651858.cd003481.pub3

Cited by 59 publications

(54 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fifty-six preterm newborns at 48-72 h of life with echocardiograph evidence of a hemodynamically significant PDA were treated intravenously with IBU according to literature data [15]. The protocol provided a course of three doses of IBU (an initial dose of 10 mg/kg, followed by two 5 mg/kg doses after 24 and 48 h).…”

Section: Methodsmentioning

confidence: 99%

Isoprostane levels in urine of preterm newborns treated with ibuprofen for patent ductus arteriosus closure

et al. 2010

View full text Add to dashboard Cite

Patent ductus arteriosus (PDA) is the most common cardiovascular abnormality of the preterm infant usually treated with ibuprofen (IBU). PDA is strictly related to oxidative stress (OS) in neonates. This study tests the hypothesis that OS occurs in neonates with PDA and that IBU treatment reduces OS. Forty-three preterm babies with gestational age (GA) <33 weeks were studied prospectively. Three urine samples were collected: at time 0 (before starting treatment), time 1 (after pharmacological PDA closure), and time 2 (7 days after the end of treatment) in all patients. OS was studied by measuring urinary isoprostane (IPs) levels. The results showed significant changes in urinary IP levels from time 0 to time 2 (Kruskal-Wallis, p=0.047). Time trend showed a significant decrease in IPs from time 0 to time 1 after IBU therapy (p=0.0067). This decrease was followed by an increase in IPs levels 7 days after treatment. IBU therapy for PDA closure reduced the risk of OS related to free-radical (FR) generation. This antioxidant effect of IBU may be beneficial in preterm babies with PDA who are at high risk for OS.

show abstract

Section: Methodsmentioning

confidence: 99%

Isoprostane levels in urine of preterm newborns treated with ibuprofen for patent ductus arteriosus closure

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Van Overmeire et al demonstrated significantly lower creatinine values (and greater urine output) in the ibuprofen group compared to indomethacin, when administered to preterm infants (24 to 32 weeks of gestation) [35]. Additionally, a recent Cochrane analysis [21] noted that ibuprofen was associated with a reduced risk of oliguria and lower serum creatinine levels following treatment.…”

Section: Discussionmentioning

confidence: 99%

Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The current recommended indication for non-steroidal anti-inflammatory drugs (NSAIDs) in the preterm neonatal period is the curative medical treatment of persistent ductus arteriosus [20]. Experimental data indicate that NSAIDs could be neuroprotective in the developing brain in the context of systemic inflammation, through a reduction in brain prostaglandin E 2 synthesis by cyclooxygenase-2 inhibition at the blood-brain barrier [21].…”

Section: Modulators Of Inflammation/infectionmentioning

confidence: 99%

Impact of Common Treatments Given in the Perinatal Period on the Developing Brain

et al. 2014

View full text Add to dashboard Cite

Background: Over the last decades, considerable progress has been made in the perinatal management of high-risk preterm neonates, changing the landscape of pathological conditions associated with neurological impairments. Major focal destructive lesions are now less common, and the predominant neuropathological lesion is diffuse white-matter damage in the most immature infants. Similarly, over the last few years, we have observed a trend towards a decrease in neurological impairment in the absence of treatments specifically aimed at neuroprotection. Objectives: We examined whether recent changes in treatment strategies in perinatal care during the perinatal period could have had an indirect beneficial impact on the occurrence of brain lesions and their consequences. Methods: Thus, we reviewed the effects of the most common treatments administered during the perinatal period to the mother or to very preterm infants on brain damage and neurocognitive follow-up. Results: Antenatal steroids and exogenous surfactant are the two main treatments capable of leading to neuroprotection in very preterm infants. Randomized controlled trials are currently investigating the effects of inhaled nitric oxide and erythropoietin, while antenatal magnesium sulphate and caffeine are also likely to provide some neuroprotection, but this needs to be further investigated. Finally, other common treatments against pain, haemodynamic failure and patent ductus arteriosus have conflicting or no effects on the developing brain. Conclusion: While specific neuroprotective drugs are still awaited, recent advances in perinatal care have been associated with an unexpected but significant decrease in the incidence of both severe brain lesions and neurological impairment.

show abstract

Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants

Cited by 59 publications

References 51 publications

Isoprostane levels in urine of preterm newborns treated with ibuprofen for patent ductus arteriosus closure

Isoprostane levels in urine of preterm newborns treated with ibuprofen for patent ductus arteriosus closure

Indomethacin vs ibuprofen: comparison of efficacy in the setting of conservative therapeutic approach

Impact of Common Treatments Given in the Perinatal Period on the Developing Brain

Contact Info

Product

Resources

About